Morgan Stanley’s INmune Bio INMB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $237K | Buy |
102,738
+18,274
| +22% | +$42.2K | ﹤0.01% | 5788 |
|
|
2025
Q1 | $660K | Sell |
84,464
-70,662
| -46% | -$552K | ﹤0.01% | 5205 |
|
|
2024
Q4 | $724K | Buy |
155,126
+62,982
| +68% | +$294K | ﹤0.01% | 5251 |
|
|
2024
Q3 | $497K | Buy |
92,144
+63,769
| +225% | +$344K | ﹤0.01% | 5411 |
|
|
2024
Q2 | $250K | Buy |
28,375
+896
| +3% | +$7.9K | ﹤0.01% | 5582 |
|
|
2024
Q1 | $323K | Buy |
27,479
+1,873
| +7% | +$22K | ﹤0.01% | 5522 |
|
|
2023
Q4 | $288K | Buy |
25,606
+21,525
| +527% | +$242K | ﹤0.01% | 5811 |
|
|
2023
Q3 | $27.6K | Sell |
4,081
-913
| -18% | -$6.18K | ﹤0.01% | 6386 |
|
|
2023
Q2 | $45.3K | Buy |
4,994
+177
| +4% | +$1.61K | ﹤0.01% | 6245 |
|
|
2023
Q1 | $31.1K | Buy |
4,817
+1,829
| +61% | +$11.8K | ﹤0.01% | 6458 |
|
|
2022
Q4 | $18.9K | Sell |
2,988
-126,012
| -98% | -$799K | ﹤0.01% | 6712 |
|
|
2022
Q3 | $800K | Sell |
129,000
-79,282
| -38% | -$492K | ﹤0.01% | 5011 |
|
|
2022
Q2 | $1.84M | Sell |
208,282
-92,199
| -31% | -$815K | ﹤0.01% | 4601 |
|
|
2022
Q1 | $2.53M | Sell |
300,481
-78,006
| -21% | -$657K | ﹤0.01% | 4342 |
|
|
2021
Q4 | $3.86M | Buy |
378,487
+353,856
| +1,437% | +$3.61M | ﹤0.01% | 3986 |
|
|
2021
Q3 | $478K | Buy |
24,631
+13,088
| +113% | +$254K | ﹤0.01% | 5524 |
|
|
2021
Q2 | $203K | Buy |
11,543
+8,450
| +273% | +$149K | ﹤0.01% | 6010 |
|
|
2021
Q1 | $37K | Buy |
3,093
+1,526
| +97% | +$18.3K | ﹤0.01% | 6491 |
|
|
2020
Q4 | $27K | Buy |
1,567
+567
| +57% | +$9.77K | ﹤0.01% | 6352 |
|
|
2020
Q3 | $10K | Buy |
+1,000
| New | +$10K | ﹤0.01% | 6276 |
|